Research & Literature

A Hypereosinophilic Syndrome with Cardiac Involvement from Thrombotic Stage to Fibrotic Stage.

Kim NK, Kim CY, Kim JH, et al.

Journal of cardiovascular ultrasound 2015; (23(2)):100-2 doi:10.4250/jcu.2015.23.2.100.

Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1.

Vega F, Medeiros LJ, Bueso-Ramos CE, et al.

American journal of clinical pathology 2015; (144(3)):377-92 doi:10.1309/AJCPMORR5Z2IKCEM.

Hypereosinophilic syndrome: cardiac diagnosis and management.

Mankad R, Bonnichsen C, Mankad S

Heart (British Cardiac Society) 2016; (102(2)):100-6 doi:10.1136/heartjnl-2015-307959.

A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.

Wang J, Zhang Q, Zeng H, et al.

Pharmacogenomics 2016; (17(2)):99-102 doi:10.2217/pgs.15.159.

Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.

Qu SQ, Qin TJ, Xu ZF, et al.

Oncotarget 2016; (7(22)):33229-36 doi:10.18632/oncotarget.8906.

Severe Prolonged Cough as Presenting Manifestation of FIP1L1-PDGFRA+ Chronic Eosinophilic Leukaemia: A Widely Ignored Association.

Roufosse F, Heimann P, Lambert F, et al.

Respiration; international review of thoracic diseases 2016; (91(5)):374-9 doi:10.1159/000446076.

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML).

El Jurdi N, Bankoff M, Klein A, Saif MW

Cureus 2016; (8(6)):e660 doi:10.7759/cureus.660.

Myeloid neoplasms with eosinophilia.

Reiter A, Gotlib J

Blood 2017; (129(6)):704-714 doi:10.1182/blood-2016-10-695973.

Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

Salem A, Loghavi S, Tang G, et al.

American journal of hematology 2017; (92(6)):520-528 doi:10.1002/ajh.24710.

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology.

Guglielmelli P, Pietra D, Pane F, et al.

Leukemia research 2017; (58()):63-72 doi:10.1016/j.leukres.2017.04.006.

Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.

Wang SA, Hasserjian RP, Tam W, et al.

Haematologica 2017; (102(8)):1352-1360 doi:10.3324/haematol.2017.165340.

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.

Jawhar M, Naumann N, Schwaab J, et al.

Annals of hematology 2017; (96(9)):1463-1470 doi:10.1007/s00277-017-3067-x.

A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.

Oberley MJ, Denton C, Ji J, et al.

Cancer genetics 2017; (216-217()):91-99 doi:10.1016/j.cancergen.2017.07.007.

World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.

Gotlib J

American journal of hematology 2017; (92(11)):1243-1259 doi:10.1002/ajh.24880.

Hypereosinophilic syndrome in the differential diagnosis of pulmonary infiltrates with eosinophilia.

Zimmermann N, Wikenheiser-Brokamp KA

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2018; (121(2)):179-185 doi:10.1016/j.anai.2018.05.014.

A multimodality work-up of patients with Hypereosinophilia.

Hu Z, Boddu PC, Loghavi S, et al.

American journal of hematology 2018; (93(11)):1337-1346 doi:10.1002/ajh.25247.

When Hypereosinophilia Leads to Stroke.

Chalayer E, Pelissier A, Tardy B

European journal of case reports in internal medicine 2017; (4(6)):000614 doi:10.12890/2017_000614.

Myeloproliferative neoplasms: Diagnostic workup of the cythemic patient.

Wong WJ, Pozdnyakova O

International journal of laboratory hematology 2019; (41 Suppl 1()):142-150 doi:10.1111/ijlh.13005.

Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.

Metzgeroth G, Schwaab J, Naumann N, et al.

Blood advances 2020; (4(3)):440-443 doi:10.1182/bloodadvances.2019001111.

An unusual presentation of Idiopathic hypereosinophilic syndrome.

Chua CE, Ling V, Jing M, et al.

Journal of thrombosis and thrombolysis 2020; (50(2)):473-476 doi:10.1007/s11239-020-02127-2.

Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients.

Rohmer J, Couteau-Chardon A, Trichereau J, et al.

American journal of hematology 2020; (95(11)):1314-1323 doi:10.1002/ajh.25945.

Loeffler's Endocarditis: An Integrated Multimodality Approach.

Polito MV, Hagendorff A, Citro R, et al.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2020; (33(12)):1427-1441 doi:10.1016/j.echo.2020.09.002.

Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.

Pozdnyakova O, Orazi A, Kelemen K, et al.

American journal of clinical pathology 2021; (155(2)):160-178 doi:10.1093/ajcp/aqaa208.

Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.

Kelemen K, Saft L, Craig FE, et al.

American journal of clinical pathology 2021; (155(2)):179-210 doi:10.1093/ajcp/aqaa244.

Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.

Helbig G, Klion AD

Blood reviews 2021; (49()):100809 doi:10.1016/j.blre.2021.100809.

Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics.

Nann D, Fend F

Cancers 2021; (13(14)) doi:10.3390/cancers13143528.

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity.

Mueller SB, Dal Cin P, Le LP, et al.

Blood advances 2022; (6(3)):818-827 doi:10.1182/bloodadvances.2021005280.

Literature reviews of stroke with hypereosinophilic syndrome.

Ono R, Iwahana T, Kato H, et al.

International journal of cardiology. Heart & vasculature 2021; (37()):100915 doi:10.1016/j.ijcha.2021.100915.

Clinical analysis of hypereosinophilic syndrome first presenting with asthma-like symptoms.

Wei X, Li X, Wei Z, et al.

Annals of medicine 2022; (54(1)):11-21 doi:10.1080/07853890.2021.2014555.

Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.

Hernández-Boluda JC, Pereira A, Zinger N, et al.

Bone marrow transplantation 2022; (57(3)):416-422 doi:10.1038/s41409-021-01553-x.

Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.

Requena G, van den Bosch J, Akuthota P, et al.

The journal of allergy and clinical immunology. In practice 2022; (10(8)):2125-2134 doi:10.1016/j.jaip.2022.03.034.

The hypereosinophilic syndrome - an unusual cause of myocarditis and cardioembolic strokes.

Ryan D, Inamullah O, El Husseini N, et al.

The American journal of the medical sciences 2022; (364(5)):661-668 doi:10.1016/j.amjms.2022.05.019.

Updates on eosinophilic disorders.

Tzankov A, Reichard KK, Hasserjian RP, et al.

Virchows Archiv : an international journal of pathology 2023; (482(1)):85-97 doi:10.1007/s00428-022-03402-8.

Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.

Pane F, Lefevre G, Kwon N, et al.

Frontiers in immunology 2022; (13()):935996 doi:10.3389/fimmu.2022.935996.

Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?

Iurlo A, Cattaneo D

Blood reviews 2023; (58()):101014 doi:10.1016/j.blre.2022.101014.

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.

Thiele J, Kvasnicka HM, Orazi A, et al.

American journal of hematology 2023; (98(1)):166-179 doi:10.1002/ajh.26751.

Two pediatric oncologic cases of hypereosinophilic syndrome and review of the literature.

Voeller J, DeNapoli T, Griffin TC

Cancer reports (Hoboken, N.J.) 2022; (5(11)):e1710 doi:10.1002/cnr2.1710.

Case Report: Pediatric myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement: The first case presenting as B-lymphoblastic lymphoma.

Akiely R, Almasri F, Almasri N, Abu-Ghosh A

Frontiers in pediatrics 2022; (10()):1059527 doi:10.3389/fped.2022.1059527.

Clinical and histopathological features of hypereosinophilic syndrome with cutaneous involvement: The Mayo Clinic Experience.

Zayas J, Peters MS, Butterfield JH, et al.

Journal of cutaneous pathology 2023; (50(5)):455-465 doi:10.1111/cup.14410.

Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Freyer CW, Hughes ME, Carulli A, et al.

Expert review of anticancer therapy 2023; (23(4)):351-359 doi:10.1080/14737140.2023.2192930.

Progression in Myeloid Neoplasms: Beyond the Myeloblast.

Faria C, Tzankov A

Pathobiology : journal of immunopathology, molecular and cellular biology 2024; (91(1)):55-75 doi:10.1159/000530940.

FIP1L1-PDGFRα-Positive Loeffler Endocarditis-A Distinct Cause of Heart Failure in a Young Male: The Role of Multimodal Diagnostic Tools.

Varga A, Moldovan DA, Pop M, et al.

Diagnostics (Basel, Switzerland) 2023; (13(10)) doi:10.3390/diagnostics13101795.

The international consensus classification of eosinophilic disorders and systemic mastocytosis.

Wang SA, Orazi A, Gotlib J, et al.

American journal of hematology 2023; (98(8)):1286-1306 doi:10.1002/ajh.26966.

HES and EGPA: Two Sides of the Same Coin.

Khoury P, Akuthota P, Kwon N, et al.

Mayo Clinic proceedings 2023; (98(7)):1054-1070 doi:10.1016/j.mayocp.2023.02.013.

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.

Metzgeroth G, Steiner L, Naumann N, et al.

Leukemia 2023; (37(9)):1860-1867 doi:10.1038/s41375-023-01958-1.

Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.

Kuang FL, Khoury P, Weller PF, et al.

The journal of allergy and clinical immunology. In practice 2023; (11(9)):2666-2671 doi:10.1016/j.jaip.2023.07.026.

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases.

Saft L, Kvasnicka HM, Boudova L, et al.

Histopathology 2023; (83(6)):829-849 doi:10.1111/his.15021.

T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.

Schoelinck J, Gervasoni J, Guillermin Y, et al.

Virchows Archiv : an international journal of pathology 2024; (484(5)):853-857 doi:10.1007/s00428-023-03693-5.

Hematological Neoplasms with Eosinophilia.

Morales-Camacho RM, Caballero-Velázquez T, Borrero JJ, et al.

Cancers 2024; (16(2)) doi:10.3390/cancers16020337.

Epidemiology and prognostic nomogram for chronic eosinophilic leukemia: a population-based study using the SEER database.

Wang J, Lin M, Wang F

Scientific reports 2024; (14(1)):4594 doi:10.1038/s41598-024-55432-8.

World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.

Shomali W, Gotlib J

American journal of hematology 2024; (99(5)):946-968 doi:10.1002/ajh.27287.

Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO study.

Groh M, Fenwarth L, Labro M, et al.

American journal of hematology 2024; (99(6)):1108-1118 doi:10.1002/ajh.27306.

Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis

Ümit EG, Baysal M, Kırkızlar HO, Demir AM

Turkish journal of haematology : official journal of Turkish Society of Haematology 2024; (41(3)):175-181 doi:10.4274/tjh.galenos.2024.2024.0011.

How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.

Reiter A, Metzgeroth G, Cross NCP

Blood 2025; (145(16)):1758-1768 doi:10.1182/blood.2023022417.

Successful novel use of dupilumab for gastrointestinal involvement of idiopathic hypereosinophilic syndrome: case report and review of the literature.

Moffatt C, Soriano C, Dawson DW, Weiss GA

Clinical journal of gastroenterology 2024; (17(6)):1003-1008 doi:10.1007/s12328-024-02036-4.

Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategies.

Costa A, Scalzulli E, Breccia M

British journal of haematology 2025; (206(1)):44-60 doi:10.1111/bjh.19921.

Cardiac Abnormalities in Hypereosinophilic Syndromes.

Hotta VT, Nastari RR, Oishi GDSL, et al.

Arquivos brasileiros de cardiologia 2024; (121(10)):e20240190 doi:10.36660/abc.20240190.

Novel ETV6::RAPGEF6 fusion gene in chronic eosinophilic leukemia: compiling evidence on the role of IL3 overexpression in tumorigenesis.

Iberti M, Loschi M, Keslair F, et al.

Annals of hematology 2025; (104(3)):2017-2021 doi:10.1007/s00277-025-06217-0.

Refractory Idiopathic Hypereosinophilic Syndrome Presenting with Myocarditis and Responding to Imatinib: A Case Report.

Albayyat RA, AlQahtani SY, Sharofna KA

Saudi journal of medicine & medical sciences 2025; (13(1)):68-72 doi:10.4103/sjmms.sjmms_503_23.

Efficacy of anti-interleukin 5 therapy in hypereosinophilic syndrome: An updated systematic review and meta-analysis.

Masood S, Paracha MR, Ahmed S, et al.

Allergy and asthma proceedings 2025; (46(2)):e24-e32 doi:10.2500/aap.2025.46.240106.

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.

Polverelli N, Hernández-Boluda JC, Onida F, et al.

Blood 2025; (145(22)):2561-2573 doi:10.1182/blood.2024028000.

Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes.

Hwee J, Huynh L, da Costa W, et al.

Frontiers in allergy 2025; (6()):1605397 doi:10.3389/falgy.2025.1605397.

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

Verstovsek S, Kiladjian JJ, Vannucchi AM, et al.

NEJM evidence 2025; (4(9)):EVIDoa2500017 doi:10.1056/EVIDoa2500017.

Organ-Restricted Hypereosinophilic Syndrome: A Case of Recurrent Hypereosinophilic Myopericarditis.

Alhajri N, Fadlelseed S, Abokhater N, et al.

JACC. Case reports 2025; (30(35)):105535 doi:10.1016/j.jaccas.2025.105535.

A Critical Case of Chronic Eosinophilic Leukemia: Diagnostic Criteria and Response to Cytarabine.

Cruz-Acevedo AK, Pérez-Campos EL, Hernández-Huerta MT, et al.

Case reports in oncological medicine 2025; (2025()):8887007 doi:10.1155/crom/8887007.

Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes.

Salmon M, Naumann N, Rinke J, et al.

Leukemia 2026; (40(1)):37-46 doi:10.1038/s41375-025-02801-5.

Ulcers and Eosinophils: A Rare Presentation of PDGFRA-Rearranged Myeloid Neoplasm Responding to Imatinib.

Calderon A, Goyal S, Loayza Pintado J, et al.

Journal of investigative medicine high impact case reports 2026; (14()):23247096251414051 doi:10.1177/23247096251414051.

Organ Involvement and Constitutional Symptoms in Idiopathic Hypereosinophilic Syndrome: A 72-Patient Single-Centre Cohort.

Łacwik P, Kupryś-Lipińska I, Kucharczyk A, et al.

Journal of clinical medicine 2026; (15(14)) doi:10.3390/jcm15145569.

Loeffler's Endomyocarditis With Embolic Stroke Secondary to Chronic Eosinophilic Leukemia With Therapy-Related Molecular Features.

Ramesh S, Yousif N, Affas Z, et al.

JACC. Case reports 2026; 109890 doi:10.1016/j.jaccas.2026.109890.

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis.

Wigerinck S, Vandenberghe P

European journal of haematology 2026; doi:10.1111/ejh.70299.

Hypereosinophilic syndrome with Löffler endocarditis and multiple cerebral infarctions in a patient with a CLL-phenotype clonal B-cell population: a case report.

Wang H, Zhu F, Hu H

Frontiers in cardiovascular medicine 2026; (13()):1924869 doi:10.3389/fcvm.2026.1924869.